Advertisement
Canada markets close in 5 hours 53 minutes

  • S&P/TSX

    21,989.93
    -21.79 (-0.10%)
     

  • S&P 500

    5,085.19
    +14.64 (+0.29%)
     

  • DOW

    38,507.82
    +4.13 (+0.01%)
     

  • CAD/USD

    0.7297
    -0.0023 (-0.32%)
     

  • CRUDE OIL

    82.92
    -0.44 (-0.53%)
     

  • Bitcoin CAD

    90,666.89
    -782.42 (-0.86%)
     

  • CMC Crypto 200

    1,429.02
    +4.92 (+0.35%)
     

  • GOLD FUTURES

    2,334.50
    -7.60 (-0.32%)
     

  • RUSSELL 2000

    2,004.92
    +2.28 (+0.11%)
     

  • 10-Yr Bond

    4.6440
    +0.0460 (+1.00%)
     

  • NASDAQ

    15,815.80
    +119.16 (+0.76%)
     

  • VOLATILITY

    15.68
    -0.01 (-0.06%)
     

  • FTSE

    8,066.17
    +21.36 (+0.27%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6817
    -0.0019 (-0.28%)
     
MARKETS LIVE BLOG:

STOCKS OPEN MIXED, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference

iBio, Inc.

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that the Company’s Chairman & CEO, Tom Isett, and its CSO, Martin Brenner, DVM, Ph.D., will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 10:00 a.m. Eastern Time.

The fireside chat will be broadcast live and archived on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com